Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin

Even today the treatment outcome of tuberculosis is questionable due to variable bioavailability of rifampicin, which was discovered four decades back. In this manuscript, results of bioequivalence trials reported are presented in the form of a figure that provides a comprehensive look at the rifamp...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2004-03, Vol.271 (1), p.1-4
Main Authors: Panchagnula, Ramesh, Agrawal, Shrutidevi
Format: Article
Language:English
Subjects:
Antibacterial agents
Antibiotics, Antitubercular - administration & dosage
Antibiotics, Antitubercular - chemistry
Antibiotics, Antitubercular - pharmacokinetics
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bioavailability
Bioequivalence
Biological and medical sciences
Biological Availability
Clinical Trials as Topic
Dosage Forms
Drug Combinations
Fixed-dose combination
General pharmacology
Humans
Medical sciences
Mycobacterium
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Rifampicin
Rifampin - administration & dosage
Rifampin - chemistry
Rifampin - pharmacokinetics
Solubility
Technology, Pharmaceutical
Tuberculosis
Tuberculosis - drug therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Even today the treatment outcome of tuberculosis is questionable due to variable bioavailability of rifampicin, which was discovered four decades back. In this manuscript, results of bioequivalence trials reported are presented in the form of a figure that provides a comprehensive look at the rifampicin bioavailability literature, provides understanding of the problem and clears ’myths and assumptions’ regarding rifampicin bioavailability from fixed-dose combination (FDC) formulations. It was found that FDCs of good as well as bad quality rifampicin containing formulations with reduced or increased relative bioavailability are available. In addition, ‘rifampicin alone’ formulations also show variability in bioavailability. In the context of anomalous bioavailability of rifampicin, reasons postulated in literature are summarized. Approaches needed to solve the issue of rifampicin bioavailability are discussed on the basis of LADMER and BCS.
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2003.11.031